NIDDK, together with the VA Cooperative Studies Program, recently funded a large therapeutic trial in ARF. This trial, known as the ARF Trial Network (ATN) study CSP530, will randomize 1164 patients at 27 centers to normal versus high-dose renal replacement therapy. Under the Program Announcement, PAR-04-078 for ancillary studies to NIDDK-funded clinical trials, we propose to augment the ATN-CSP 530 Study with an evaluation of a set of candidate biological markers of recovery for the kidney (BioMaRK). Preliminary evidence suggests genetic, inflammatory, and clinical factors all play a role and there is mounting interest in the question of whether the way in which renal replacement therapy is provided influences the clinical course. The central goal of BioMaRK is to better understand the role of two key pathways, inflammation and oxidative stress, in survival and recovery of renal function after ARF. We will also look at genetic variation, not only in genes coding for inflammatory mediators, but also other key components of the injury-to-repair continuum. Additionally, we will seek new markers of renal injury and repair by mass spectrometric examination of the urine. Finally, in keeping with the NIH Roadmap, in order to understand the clinical utility of this work, we will build a clinical risk prediction model that will consider plasma mediator levels, urine markers, genetic, and clinical variables. We will use the ATN-CSP 530 trial cohort as an inception cohort of patients with newly established ARF. For most analyses, we propose to study the entire portion of the ATN-CSP530 trial cohort that consents to the blood sample and DNA bank (815 patients). For analyses requiring serial samples and urine samples, we propose to study a subset of trial patients enrolled at 5 sites who consent to additional sample collection (208 patients)

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Research Project (R01)
Project #
5R01DK070910-05
Application #
7920242
Study Section
Special Emphasis Panel (ZDK1-GRB-G (O2))
Program Officer
Eggers, Paul Wayne
Project Start
2006-09-01
Project End
2012-05-31
Budget Start
2010-06-01
Budget End
2012-05-31
Support Year
5
Fiscal Year
2010
Total Cost
$344,986
Indirect Cost
Name
University of Pittsburgh
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
004514360
City
Pittsburgh
State
PA
Country
United States
Zip Code
15213
Leaf, David E; Siew, Edward D; Eisenga, Michele F et al. (2018) Fibroblast Growth Factor 23 Associates with Death in Critically Ill Patients. Clin J Am Soc Nephrol 13:531-541
Wenzel, Sally E; Tyurina, Yulia Y; Zhao, Jinming et al. (2017) PEBP1 Wardens Ferroptosis by Enabling Lipoxygenase Generation of Lipid Death Signals. Cell 171:628-641.e26
Kellum, John A; Sileanu, Florentina E; Bihorac, Azra et al. (2017) Recovery after Acute Kidney Injury. Am J Respir Crit Care Med 195:784-791
Kim, Yeonhee; Kong, Lan (2016) Classification using longitudinal trajectory of biomarker in the presence of detection limits. Stat Methods Med Res 25:458-71
Singbartl, Kai; Miller, Lauren; Ruiz-Velasco, Victor et al. (2016) Reversal of Acute Kidney Injury-Induced Neutrophil Dysfunction: A Critical Role for Resistin. Crit Care Med 44:e492-501
Ring, Troels; Kellum, John A (2016) Strong Relationships in Acid-Base Chemistry - Modeling Protons Based on Predictable Concentrations of Strong Ions, Total Weak Acid Concentrations, and pCO2. PLoS One 11:e0162872
Kellum, John A; Sileanu, Florentina E; Murugan, Raghavan et al. (2015) Classifying AKI by Urine Output versus Serum Creatinine Level. J Am Soc Nephrol 26:2231-8
Kellum, John A (2015) Diagnostic Criteria for Acute Kidney Injury: Present and Future. Crit Care Clin 31:621-32
Kim, Yeonhee; Kong, Lan (2015) Estimation of C-index for cox proportional hazards model with censored biomarker covariate subject to limits of detection. J Biopharm Stat 25:459-73
Murugan, Raghavan; Wen, Xiaoyan; Keener, Christopher et al. (2015) Associations between Intensity of RRT, Inflammatory Mediators, and Outcomes. Clin J Am Soc Nephrol 10:926-33

Showing the most recent 10 out of 26 publications